Deutsche Bank maintains a 'Buy' rating on Gilead Sciences despite a voluntary recall of Atripla due to minor quality issues. The recall involved 39,000 bottles from a third-party manufacturer in China. Gilead has sufficient supply and multiple manufacturers for Atripla. The report reiterates a $132 price target for Gilead, emphasizing the strength of its base business and Sovaldi.
documents/vol00010-efta01462405-pdf.pdf
{"title":"Deutsche Bank Markets Research on Gilead Sciences","key_people":["Robyn Karnauskas","Alethia Young"],"document_date":"2014-03-06","document_type":"correspondence","key_locations":["United States","China"],"document_subtype":"research report","key_organizations":["Deutsche Bank","Gilead Sciences","FDA"],"reference_numbers":["EFTA01462405","EFTA01462406","EFTA01462407"]}